82 results
8-K
CHRS
Coherus Biosciences Inc
14 May 18
Departure of Directors or Certain Officers
5:22pm
, health care systems and provider organizations. He also serves as a Senior Advisor to Sandbox Industries, a health care venture fund and the Ontario … to joining Anthem, Dr. Nussbaum served as executive vice president, Medical Affairs and System Integration of BJC Health Care. Dr. Nussbaum had a20
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
14 May 18
Departure of Directors or Certain Officers
5:22pm
, Inc. (Nasdaq: CHRS), today announced the appointment of Samuel Nussbaum, M.D. to its Board of Directors.
“We are thrilled to have a health care policy … , and leadership will make significant contributions to our efforts to deliver much needed treatments to patients and savings to the health care system,” said
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Aug 20
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
4:19pm
, President and CEO of Coherus. “Ms. Tzoumakas’ executive leadership experience in the health care sector, including in her current role as CEO of GenesisCare … served as general counsel and as a member of its leadership team. Prior to 21st Century Oncology, Ms. Tzoumakas practiced health care law with Hall
8-K
CHRS
Coherus Biosciences Inc
6 Aug 20
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
4:19pm
November 2001 to April 2018, Ms. Tzoumakas practiced health care law with Hall Render Killian Heath & Lyman, providing strategic, transactional … and governance advice to health care clients throughout the country. While at Hall Render, she was also a long-term managing partner of the firm’s Michigan
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
29 Sep 21
Departure of Directors or Certain Officers
5:07pm
Anthem, Dr. Nussbaum served as a strategic advisor to life science companies, health care systems and provider organizations, and life science investors … have a major impact on patients’ lives and to deliver significant savings to the health care system. For additional information, please visit
D
3nbxtgwi
14 Jan 13
$61.47M in equity / securities to be acquired, sold $46.27M, 23 investors
12:00am
D/A
rug9ut v57s12oubfjyt
3 Jan 12
$14.32M in debt / options / securities to be acquired, sold $12.85M, 15 investors
12:00am
D
2iq1rs i9
23 Feb 11
$375K in debt / options / securities to be acquired, sold $239.92K, 5 investors
12:00am
D
lks 8mbngc
25 Jul 11
$8.32M in debt / options / securities to be acquired, sold $3.79M, 11 investors
12:00am
D
5b78h0j
10 Mar 11
$1.57M in equity / securities to be acquired, sold $865.67K, 11 investors
12:00am
8-K
yvx6 eoi62ww0lz
7 Feb 22
Departure of Directors or Certain Officers
5:17pm
8-K
EX-99.1
8bxxl5zn8 kr0k85d
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
8-K
EX-2.1
2vtrz36gk0s9t0 p5
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
tb7 wh9o0k28heg
13 Oct 21
Departure of Directors or Certain Officers
5:01pm
8-K
EX-99.1
5w211acfxo6gi
7 Jan 21
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
4:15pm
425
2ac5y
16 Jun 23
Business combination disclosure
7:09am
425
5eb 3b52i
16 Jun 23
Business combination disclosure
8:08am